40 International Experts in Alzheimer's Claim Deep Changes in Patient Care Systems

40 Scientists and experts in Alzheimer’s disease have called on profound changes in healthcare systems, public policy and social situations to ensure that patients benefit from accelerated diagnostic and treatment developments. Alzheimer’s disease is the reason behind about 70% of cases of dementia in the world, as it is one of the most prominent causes of disability among the elderly, which imposes large social and economic burdens on families and health systems. Scientists and experts, in the research articles published by the Lancet, pointed out the developments in the diagnosis and medicine of Alzheimer’s, and the latest diagnostic methods, the future of Alzheimer’s treatments and possible ways to prevent from them. The first article was about a group of major scientific breakthroughs seen by Alzheimer’s research over the past year, with the rise of a new generation of medicine known as the antibodies of the anti-beta amyloid antibiotic, especially Likanimab and Donnimab. These medicines do not temporarily reduce the symptoms like traditional medication; On the contrary, the molecular mechanism that causes the disease targets by removing the accumulation of toxic protein in the brain. The results of the clinical trials showed the ability of this medication to delay the cognitive and functional decline for several months and then years, opening the door for the first time in the direction of an actual intervention that changes the course of the disease instead of living with it only. But the road is not paved, as this medicine contains the risk of brain complications, known as the image disorders associated with amydied such as bleeding and edema, which are accurate follow -up by regular magnetic resonance imaging, and its effectiveness varies according to the biological stage of the disease, as it appears that the greatest beneficiary is in the early stages. Alzheimer’s more than 55 million people around the world have dementia, between 60 and 70% of them due to Alzheimer’s. Expectations of the number of cases up to 139 million by 2050. 71 % of people with dementia live in low and medium income countries. Early Alzheimer’s: 1 in 13 patients, who were injured before the age of 65. The development of the disease: The changes in the brain may begin 20 or more symptoms before the symptoms appear. Experts believe that these developments get a huge burden on healthcare systems, especially in low -income countries, as treatment requires the availability of advanced magnetic resonance devices and tests for important smiles; Of the marrow fluid or by a tomography of the forestteron version, as well as multidisciplinary medical crews such as ‘oncology boards’ in the treatment of cancer. Experts have warned that the various capabilities between countries would lead to the expansion of a healthy justice, and the treatment would make exclusive to the rich, but they expected this medicine to pay more people to early diagnosis and to form the networks faster and effectively. The important indicators of Alzheimer’s disease and experts in the second article have reviewed the latest diagnostic practices and the patient’s model journey in specialized environments, as doctors do a clear diagnosis to determine whether Alzheimer’s diseases – the deposition of beta -amyloid in the brain and the hyperactivity of TAO – contributes to poor perception. The vital indicators that indicate that the imbalance of beta amyloid and OO, measured by using the Oxtured Tomography and analyzing the olive fluid, provides a diagnosis at molecular level, which is a compulsory step to determine the qualifying amyloidal -approved amyloidal. The researchers expected the vital blood indicators, which are easy to access, and already available in some countries, the diagnosis of the disease will revive, and that significant changes in healthcare systems around the world will cause. The future of the treatment of Alzheimer’s, experts in the third article, referred to the future of Alzheimer’s treatment and the way to occur from it, and explains that medicine is currently facing a milestone in a fight that lasted a century with the disease; For the first time, the researchers, through a medicine intervention installed in the third phase in clinical experiments, can reduce the accumulation of beta-amidid protein in the brain and delay the rate of cognitive and functional decline. They explained that this achievement, which was achieved thanks to the medicine of unilateral antibodies such as Likanimab and Donnimab, has provoked widespread controversy in scientific and medical circles, as some welcomed it as the beginning of a ‘new era’ in the treatment of dementia, while others have seen that the benefits are still limited. The experts pointed out that this dispute did not emerge from a vacuum, as the experiments showed that the new medicine does not stop the disease completely, but would rather delay between 27 and 36% in 18 months, which is a difference that may mean that the patient is able to drive a car or to take care of himself for a longer period, but in the same time it can cause a radical. Serious competition can cause. Edema, which are dangers that are accurate and expensive follow -up by magnetic resonance tests and genetic investigations to detect mutations that increase the possibility of complications. Alzheimer’s diagnosis appears before the symptoms and the medicine field sees a different core in diagnostic instruments, as new biomedical and bloody indicators, such as P-tau217 tests, can detect brain changes associated with Alzheimer’s before symptoms with a full contract or more. Scientists believe that these developments raise a strategic question; Is it necessary to start investigating millions of healthy people for early detection of the disease, just as in cancer tests? What does this mean in an economic and moral aspect? The researchers believe that the future is open to different scenarios, as the antibodies can determine their position as the first ‘treatment of the path of the disease’, or its role can be limited to a temporary bridge to safer and more effective medicine that does not target -amyloid roads. Scientists believe that in any case, the biggest challenge is politically and socially related to those who decide the value of the time granted to the patient before losing his independence? Does health systems carry this burden in the light of priorities, no less urgent? They pointed out that there is progress in the field of prevention, which is health services that determine people most vulnerable to the disease and offer them personal treatment programs. However, most Alzheimer’s patients remain a low or medium risk group, making common population measures – such as a healthy urban design, limiting alcohol and sugar -like drinks – indispensable protection instruments. Experts emphasized that the rapid development of science must be adhered to by an accelerated reform in health and societal policies and structures. The head of the research team, Giovanni Farizouni, a researcher at the University of Geneva in Switzerland, said that blood tests and biological agents for Alzheimer’s, together with preventative interventions, provide exciting new horizons. He added: “But the traditional needs of patients will not disappear; we would rather need more doctors who specialize in dementia to keep working on behavioral care, careful diagnosis, psychological and social support, and therefore by making a social effort in this direction to ensure that patients today and tomorrow ensure the fruits of scientific and technological advances.”